



Biotech Sepal Pharma Reinforces Management Team and Appoints

Frédéric Revah, as Chief Executive Officer

Biotech and Pharma Industry Expert to head up the company growth

Paris, France, and Nes Ziona, Israel, Wednesday May 14th – The privately-held biotechnology company Sepal Pharma (www.sepalpharma.com), specialized in the development of novel anti-cancer drug-candidates derived from the jasmonate family of compounds, today announced the appointment of Dr. Frédéric Revah as Chief Executive Officer. M. Revah has more than 20 year experience in the pharmaceutical and biotechnology industries, as well as in the academic sector. He joined Sepal Pharma in May 2008 and is based in Paris.

Sepal has developed a novel class of anticancer drugs derived from jasmonate. The mechanism of action of jasmonates allows them to selectively target cancer cells vs normal cells. These New Chemical Entities (NCEs) selectively target cancer cells by interfering with the abnormal energy metabolism of tumor cells that is called “*the Warburg effect*”. The importance of the Warburg effect in the malignant behaviour of cancer cells has been strongly established since its initial discovery. By disrupting the specific energy synthesis cascades in cancer cells, Sepal produces drug candidates with broad therapeutic cancer indications (“pan-cancer”) – over 70% of all cancers display the Warburg effect - and with limited side-effects.

“I am very happy to be heading up Sepal Pharma where I will be working with a dynamic and experienced team,” said Dr. Frédéric Revah, CEO of Sepal Pharma. “I am very impressed with the company’s breakthrough technology approach, solid IP and unique internal know-how, as well as the high potential of its drug-candidate portfolio. Sepal’s jasmonate derivatives, have the potential of generating a unique novel therapeutic family for the treatment of cancer.” added Frédéric Revah.

“We are very pleased to welcome Frédéric, who has considerable experience in the biotech and pharma sectors, and expertise in drug discovery and corporate development” said Max Herzberg, PhD., Chairman of Sepal Pharma. “I am convinced that he will help the company grow and achieve his objectives,” added Max Herzberg.

Prior to joining Sepal, Frédéric Revah served as Vice President Drug Discovery, then Chief Scientific Officer of the listed Drug Discovery Company Cerep from 1999 to 2007, as well as Chief Executive Officer of Cerep’s oncology subsidiary. At Cerep he has been responsible for the global company platform (250 scientists) and responsible for several New Chemical Entities brought to clinic. Frédéric Revah was a Department Head in the research division of Rhone Poulenc Rorer from 1992 to 1998, and Associate Scientist at Institut Pasteur, with a tenure position, from 1990 to 1992. Frédéric Revah received his PhD. from Institut Pasteur in 1991, and obtained his engineer degree from Ecole Polytechnique in 1985.

About Sepal Pharma

Founded in 2003, Sepal Pharma is a biotechnology company developing novel anti-cancer drug candidates, derived from the jasmonate family of compounds. These New Chemical Entities (NCEs) are selectively active against cancer cells with limited side-effects and can be used in broad therapeutic cancer indications (“pan-cancer”).

Sepal Pharma’s breakthrough technology is based on Professor Eliezer Flescher’s (the Tel-Aviv University) research on the anticancer effect of jasmonates. Sepal’s lead compound has undergone preliminary Phase I trial in CLL patients, and its novel NCEs are in preclinical stage. Sepal holds a strong and unique intellectual property portfolio on the jasmonates in the oncology field. It ensures the company scientific leadership and competitive advantage over competitors.

The company collaborates with prestigious partners from both the academic and industrial worlds, including: Ariana Pharmaceuticals, Tel Aviv University, Kaplan Medical Center, Pasteur Institute, INSERM, Hopital Pitié Salpêtrière, etc..

Sepal Pharma counts 10 employees and is headquartered in Paris, France, with its laboratories in Nes Ziona, Israel. You can visit our web site at: www.sepalpharma.com

Contacts

Sepal Pharma

Frédéric Revah, PhD.

CEO

frederic.revah@sepalpharma.com

ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59

caroline@alizerp.com